Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
01
Overview
N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide is an experimental small molecule compound belonging to the class of biphenyl derivatives. It has not been approved for use in any country and is not currently indicated for any medical condition. The compound has demonstrated binding affinity (Ki = 10 nM) for mitogen‑activated protein kinase 14 (MAPK14), suggesting it acts as an inhibitor of this target. MAPK14 (also known as p38α) is involved in cellular responses to stress and inflammation; thus, inhibitors are being explored for potential anti-inflammatory or other therapeutic effects. No clinical trials have been reported beyond preclinical or early research stages[1].
- Other names
- N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
02
Targets
MAPK14 (p38 mitogen-activated protein kinase alpha)
Beyond the preview
Go deeper on N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide.